Blog

+91 9342179224
EMERGENCY SERVICE

ECMO (Extracorporeal Membrane Oxygenation)

ECMO (Extracorporeal Membrane Oxygenation) is a life-saving intervention used to support patients with severe respiratory and/or cardiac failure. ECMO provides temporary support to the heart and lungs when conventional therapies, such as mechanical ventilation or medications, are no longer sufficient. It acts as a form of cardiopulmonary bypass, taking over the function of the heart and lungs outside the body.

Types of ECMO:

  1. VA-ECMO (Venoarterial ECMO):

    • Supports both heart and lung function.
    • Blood is drained from the venous system, oxygenated outside the body, and then returned to the arterial system.
    • Used for patients with cardiogenic shock, cardiac arrest, or severe heart failure.

  2. VV-ECMO (Venovenous ECMO):

    • Supports only lung function.
    • Blood is drained from the venous system, oxygenated, and returned to the venous system.
    • Primarily used for severe respiratory failure (e.g., ARDS, pneumonia, or lung transplantation).

Indications for ECMO:

  1. Cardiac indications (for VA-ECMO):

    • Refractory cardiac arrest.
    • Cardiogenic shock.
    • Acute myocardial infarction with shock.
    • Post-cardiac surgery failure.
    • Severe heart failure unresponsive to pharmacological treatment.

  2. Respiratory indications (for VV-ECMO):

    • Acute Respiratory Distress Syndrome (ARDS).
    • Severe pneumonia.
    • Inhalation injury.
    • Post-lung transplantation support.
    • Severe asthma or COPD exacerbation.

ECMO Management Steps:

  1. Patient Selection and Evaluation:

    • Determine if the patient meets ECMO criteria based on severity of disease, failure of conventional therapy, and reversible causes.
    • Multidisciplinary team (intensivists, cardiologists, surgeons, perfusionists) is typically involved in decision-making.

  2. Vascular Access:

    • VA-ECMO: Requires large bore cannulas placed in both the venous and arterial systems. Usually, a venous cannula is placed in the femoral or jugular vein, and an arterial cannula in the femoral or axillary artery.
    • VV-ECMO: Vascular access is usually in the femoral vein, internal jugular vein, or both.

  3. Cannulation:

    • Cannula placement is done under sterile conditions, often in an operating room or intensive care unit.
    • Ultrasound guidance is commonly used for accurate placement.
    • Placement of a large-bore cannula in the femoral vein and artery is the most common, though other sites (e.g., jugular veins) may be used.

  4. ECMO Circuit:

    • Blood is drained via the cannula, passed through a pump, oxygenator (membrane lung), and then returned to the patient.
    • The pump provides the necessary flow and pressure, while the oxygenator adds oxygen and removes carbon dioxide.
    • Anticoagulation is required to prevent clotting in the circuit.

  5. Anticoagulation:

    • Patients on ECMO need continuous anticoagulation (usually with heparin) to prevent clot formation.
    • Target therapeutic range is monitored through activated clotting time (ACT) or activated partial thromboplastin time (aPTT).
    • Frequent monitoring of platelet count, hemoglobin, and hematocrit is necessary to avoid complications such as bleeding or clotting.

  6. Hemodynamic and Respiratory Monitoring:

    • Continuous monitoring of blood gases, oxygenation, and cardiac output.
    • Echocardiography and/or cardiac output monitoring help assess heart function.
    • Pulmonary function is assessed to monitor the effectiveness of VV-ECMO.
    • Adjustments in ECMO flow rates are based on clinical parameters and gas exchange requirements.

  7. Weaning from ECMO:

    • The decision to wean from ECMO is made based on improvements in the patient’s underlying condition.
    • Gradual reduction in support is done to assess the patient’s ability to tolerate reduced ECMO flow.
    • Weaning criteria include improvement in oxygenation, cardiac output, or lung compliance.
    • When the patient is stable, ECMO support can be gradually reduced until it is no longer necessary, followed by explantation.

  8. Complications to Monitor for:

    • Bleeding: Due to anticoagulation therapy, bleeding is a significant risk. Close monitoring of coagulation parameters is essential.
    • Infection: The patient is at risk for infections related to cannulation sites or systemic infection.
    • Thrombosis: Clot formation in the ECMO circuit can lead to pump failure or embolism.
    • Neurological issues: The patient is at risk for stroke or other neurological complications due to embolism or hypoxia.
    • Organ Dysfunction: Long-term use of ECMO can lead to renal failure, liver dysfunction, or other organ impairments.

  9. Duration of ECMO:

    • The length of ECMO support varies depending on the underlying cause of failure and the patient's progress.
    • Short-term support (days to weeks) is more common for reversible conditions (e.g., ARDS, cardiogenic shock).
    • Prolonged ECMO can lead to increased risks, including multiple organ dysfunction syndrome (MODS).

  10. Multidisciplinary Care:

    • Intensive care unit (ICU) team: Critical care specialists, respiratory therapists, perfusionists, and nursing staff are essential for day-to-day management.
    • Regular consultation with specialists (e.g., cardiologists, pulmonologists, surgeons) is often necessary.
    • Rehabilitation: Post-ECMO recovery may require physical therapy to help the patient regain strength, especially after prolonged support.

Key Considerations:

  • Early initiation of ECMO can improve outcomes in patients with severe respiratory or cardiac failure.
  • ECMO requires continuous and careful monitoring due to its high-risk nature, involving many systems.
  • The goal is to support the patient long enough for recovery of the underlying condition, with careful planning for both initiation and weaning.

Effective ECMO management involves a well-coordinated, skilled team approach with a focus on individualized care for each patient.